Conference Track

Chronic Myeloid Leukemia

Source: CCO Independent Conference Coverage of the American Society of Hematology 2007 Annual Meeting*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Dasatinib Superior to High-Dose Imatinib in Patients With Imatinib-Resistant Chronic-Phase Chronic Myeloid Leukemia After 2-Year Follow-up
Responses to Dasatinib in Patients With Imatinib-Resistant/Intolerant Chronic-Phase CML Maintained in 2-Year Follow-up of START-C Trial
Response to Imatinib Sustained in 6-Year Follow-up With Continued Safety in Newly Diagnosed Chronic-Phase CML
Time to Complete Cytogenetic Response Does Not Predict Outcomes in Chronic-Phase CML Treated With Imatinib
Dasatinib Induces High Response Rates and Is Well Tolerated in Treatment-Naive Patients With Early CP CML
Low Sensitivity BCR-ABL Mutants Identified in Vitro Correspond With Reduced Response to Dasatinib in Patients With Chronic-Phase CML
INNO-406 Active and Well Tolerated in Patients With Ph-Positive CML and ALL Who Have Failed Multiple Tyrosine Kinase Inhibitors
Bosutinib Active and Well Tolerated in Heavily Pretreated Patients With Chronic-Phase CML
Nilotinib Active and Safe in Patients With Imatinib-Resistant/Intolerant Chronic-Phase Chronic Myeloid Leukemia
Pretransplant Imatinib During First Chronic Phase Associated With Improved Survival in CML

Expert Analysis

Expert Analysis: Chronic Myeloid Leukemia

Program Director: Roy A. Beveridge, MD

Faculty:

Brian Druker, MD
Charles L. Sawyers, MD
Moshe Talpaz, MD

Moderator: Allen S. Yang, MD, PhD

Learning Objectives

Upon completion of this activity, participants should be able to:

Cite recent data using second-generation tyrosine kinase inhibitors for the treatment of patients with chronic myeloid leukemia who are resistant to imatinib
Discuss the potential role of second-generation tyrosine kinase inhibitors in the frontline treatment of chronic myeloid leukemia
Describe results with new molecular targeting agents undergoing evaluation in chronic myeloid leukemia
Summarize the importance of the mutational status in the management of patients chronic myeloid leukemia
Recall data on long-term outcomes in patients with chronic myeloid leukemia treated with imatinib

CME CREDIT INFORMATION

Release Date: 02/28/08

Expiration Date: 02/27/09

Physicians: maximum of 0.75 AMA PRA Category 1 Credits™

Registered Nurses: 1.0 Nursing CE credit

Pharmacists: 1.0 contact hour (0.1 CEUs)

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.